-
1
-
-
0034671806
-
Cox-2 is expressed in human pulmonary, colonic, and mammary tumors
-
Soslow RA Dannenberg AJ Rush D et al. Cox-2 is expressed in human pulmonary, colonic, and mammary tumors Cancer 2000 89 2637 45
-
(2000)
Cancer
, vol.89
, pp. 2637-45
-
-
Soslow, R.A.1
Dannenberg, A.J.2
Rush, D.3
-
2
-
-
0037295004
-
Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer
-
Steele VE Hawk ET Viner JL Lubbet RA Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer Mutat Res 2003 523-524 137 44
-
(2003)
Mutat Res
, vol.523-524
, pp. 137-44
-
-
Steele, V.E.1
Hawk, E.T.2
Viner, J.L.3
Lubbet, R.A.4
-
3
-
-
0035183413
-
Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs
-
Garcia-Rodriguez LA Huerta-Alvarez C Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs Epidemiology 2001 12 88 93
-
(2001)
Epidemiology
, vol.12
, pp. 88-93
-
-
Garcia-Rodriguez, L.A.1
Huerta-Alvarez, C.2
-
4
-
-
0032815072
-
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis
-
Fischer SM Lo HH Gordon GB et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis Mol Carcinog 1999 25 231 40
-
(1999)
Mol Carcinog
, vol.25
, pp. 231-40
-
-
Fischer, S.M.1
Lo, H.H.2
Gordon, G.B.3
-
5
-
-
0035571588
-
Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis
-
Abou-Issa HM Alshafie GA Seibert K Koki AT Masferrer JL Harris RE Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis Anticancer Res 2001 21 3425 32
-
(2001)
Anticancer Res
, vol.21
, pp. 3425-32
-
-
Abou-Issa, H.M.1
Alshafie, G.A.2
Seibert, K.3
Koki, A.T.4
Masferrer, J.L.5
Harris, R.E.6
-
7
-
-
0034099597
-
Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder
-
Shirahama T Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder Clin Cancer Res 2000 6 2424 30
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2424-30
-
-
Shirahama, T.1
-
8
-
-
0033401645
-
Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine
-
Kitayama W Denda A Okajima E Tsujiuchi T Konishi Y Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine Carcinogenesis 1999 20 2305 10
-
(1999)
Carcinogenesis
, vol.20
, pp. 2305-10
-
-
Kitayama, W.1
Denda, A.2
Okajima, E.3
Tsujiuchi, T.4
Konishi, Y.5
-
9
-
-
0037366062
-
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder
-
Shariat SF Kim JH Ayala GE Kho K Wheeler TM Lerner SP Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder J Urol 2003 169 938 42
-
(2003)
J Urol
, vol.169
, pp. 938-42
-
-
Shariat, S.F.1
Kim, J.H.2
Ayala, G.E.3
Kho, K.4
Wheeler, T.M.5
Lerner, S.P.6
-
10
-
-
0034667354
-
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats
-
Grubbs CJ Lubet RA Koki AT et al. Celecoxib inhibits N-butyl-N-(4- hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats Cancer Res 2000 60 5599 602
-
(2000)
Cancer Res
, vol.60
, pp. 5599-602
-
-
Grubbs, C.J.1
Lubet, R.A.2
Koki, A.T.3
-
11
-
-
0031725297
-
Exogenous epidermal growth factor exerts promoting action during the early phase of rat urinary bladder carcinogenesis
-
Hattori K Fujimoto K Tamatani T Rademaker A Oyasu R Exogenous epidermal growth factor exerts promoting action during the early phase of rat urinary bladder carcinogenesis Jpn J Cancer Res 1998 89 991 4
-
(1998)
Jpn J Cancer Res
, vol.89
, pp. 991-4
-
-
Hattori, K.1
Fujimoto, K.2
Tamatani, T.3
Rademaker, A.4
Oyasu, R.5
-
12
-
-
0030980531
-
Significance of urinary of epidermal growth factor and its receptor expression in human bladder cancer
-
Chow NH Liu HS Chang CJ et al. Significance of urinary of epidermal growth factor and its receptor expression in human bladder cancer Anticancer Res 1997 17 1293 6
-
(1997)
Anticancer Res
, vol.17
, pp. 1293-6
-
-
Chow, N.H.1
Liu, H.S.2
Chang, C.J.3
-
13
-
-
0030608636
-
Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide
-
Dinney CP Parker C Dong Z et al. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide Clin Cancer Res 1997 3 161 8
-
(1997)
Clin Cancer Res
, vol.3
, pp. 161-8
-
-
Dinney, C.P.1
Parker, C.2
Dong, Z.3
-
14
-
-
0036005846
-
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer
-
Raben D Helfrich BA Chan D Johnson G Bunn PA ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer Semin Oncol 2002 29 Suppl. 4 37 46
-
(2002)
Semin Oncol
, vol.29
, Issue.4 SUPPL.
, pp. 37-46
-
-
Raben, D.1
Helfrich, B.A.2
Chan, D.3
Johnson, G.4
Bunn, P.A.5
-
15
-
-
0036569870
-
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
-
Ranson M Hammond LA Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 2002 20 2240 50
-
(2002)
J Clin Oncol
, vol.20
, pp. 2240-50
-
-
Ranson, M.1
Hammond, L.A.2
Ferry, D.3
-
16
-
-
0033827119
-
Combinatorial chemoprevention of intestinal neoplasia
-
Torrance CJ Jackson PE Montgomery E et al. Combinatorial chemoprevention of intestinal neoplasia Nat Med 2000 6 1024 8
-
(2000)
Nat Med
, vol.6
, pp. 1024-8
-
-
Torrance, C.J.1
Jackson, P.E.2
Montgomery, E.3
-
17
-
-
0036313660
-
Telomerase is upregulated in irreversible preneoplastic lesions during bladder carcinogenesis in rats
-
Shimazui T Ami Y Miyanaga N Ideyama Y Nakahara T Akaza H Telomerase is upregulated in irreversible preneoplastic lesions during bladder carcinogenesis in rats Jpn J Cancer Res 2002 93 495 500
-
(2002)
Jpn J Cancer Res
, vol.93
, pp. 495-500
-
-
Shimazui, T.1
Ami, Y.2
Miyanaga, N.3
Ideyama, Y.4
Nakahara, T.5
Akaza, H.6
-
20
-
-
0032528189
-
Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine
-
Okajima E Denda A Ozono S et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine Cancer Res 1998 58 3028 31
-
(1998)
Cancer Res
, vol.58
, pp. 3028-31
-
-
Okajima, E.1
Denda, A.2
Ozono, S.3
-
21
-
-
0034526574
-
Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression
-
el-Marjou A Delouvee A Thiery JP Radvanyi F Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression Carcinogenesis 2000 21 2211 8
-
(2000)
Carcinogenesis
, vol.21
, pp. 2211-8
-
-
El-Marjou, A.1
Delouvee, A.2
Thiery, J.P.3
Radvanyi, F.4
-
22
-
-
0037298141
-
New directions for ZD1839 in the treatment of solid tumors
-
Schiller JH New directions for ZD1839 in the treatment of solid tumors Sem Oncol 2003 30 Suppl. 1 49 55
-
(2003)
Sem Oncol
, vol.30
, Issue.1 SUPPL.
, pp. 49-55
-
-
Schiller, J.H.1
-
23
-
-
2442565728
-
Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
-
Nutt JE Lazarowicz HP Mellon JK Lunec J Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2 Br J Cancer 2004 90 1679 85
-
(2004)
Br J Cancer
, vol.90
, pp. 1679-85
-
-
Nutt, J.E.1
Lazarowicz, H.P.2
Mellon, J.K.3
Lunec, J.4
-
24
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ Bell DW Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 2004 350 2129 39
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-39
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
25
-
-
0037214178
-
Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: Potential targets for chemoprevention and systemic therapy
-
Richardson CM Sharma RA Cox G O'Byrne KJ Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy Lung Cancer 2003 39 1 13
-
(2003)
Lung Cancer
, vol.39
, pp. 1-13
-
-
Richardson, C.M.1
Sharma, R.A.2
Cox, G.3
O'Byrne, K.J.4
|